YPD-30 has significant anticancer performance
ADC评论
July 7, 2022
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer ScienceDirect Cancer immunotherapy is a breakthrough for
